{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T22:38:20Z","timestamp":1769121500386,"version":"3.49.0"},"reference-count":52,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2018,9,9]],"date-time":"2018-09-09T00:00:00Z","timestamp":1536451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Kyowa Hakko Kirin Co."},{"name":"PhoenixBio Co."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1,1]]},"DOI":"10.1093\/toxsci\/kfy228","type":"journal-article","created":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T11:49:57Z","timestamp":1536234597000},"page":"190-201","source":"Crossref","is-referenced-by-count":19,"title":["Chimeric Mice With Humanized Livers Demonstrate Human-Specific Hepatotoxicity Caused by a Therapeutic Antibody Against TRAIL-Receptor 2\/Death Receptor 5"],"prefix":"10.1093","volume":"167","author":[{"given":"Kaito","family":"Nihira","sequence":"first","affiliation":[{"name":"Translational Research Unit, Kyowa Hakko Kirin Co., Ltd., Nagaizumi-cho, Sunto-gun, Shizuoka 411-8731, Japan"},{"name":"Laboratory of Molecular Toxicology, School of Pharmaceutical Sciences, University of Shizuoka, Suruga-ku, Shizuoka 422-8526, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken-ichiro","family":"Nan-ya","sequence":"additional","affiliation":[{"name":"Translational Research Unit, Kyowa Hakko Kirin Co., Ltd., Nagaizumi-cho, Sunto-gun, Shizuoka 411-8731, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Kakuni","sequence":"additional","affiliation":[{"name":"PhoenixBio Co., Ltd., Higashihiroshima, Hiroshima 739-0046, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Ono","sequence":"additional","affiliation":[{"name":"Translational Research Unit, Kyowa Hakko Kirin Co., Ltd., Nagaizumi-cho, Sunto-gun, Shizuoka 411-8731, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukitaka","family":"Yoshikawa","sequence":"additional","affiliation":[{"name":"Translational Research Unit, Kyowa Hakko Kirin Co., Ltd., Nagaizumi-cho, Sunto-gun, Shizuoka 411-8731, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Ota","sequence":"additional","affiliation":[{"name":"Translational Research Unit, Kyowa Hakko Kirin Co., Ltd., Nagaizumi-cho, Sunto-gun, Shizuoka 411-8731, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Hiura","sequence":"additional","affiliation":[{"name":"Translational Research Unit, Kyowa Hakko Kirin Co., Ltd., Nagaizumi-cho, Sunto-gun, Shizuoka 411-8731, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2027-2017","authenticated-orcid":false,"given":"Kouichi","family":"Yoshinari","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Toxicology, School of Pharmaceutical Sciences, University of Shizuoka, Suruga-ku, Shizuoka 422-8526, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,9,9]]},"reference":[{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B1","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/toxsci\/kfq009","article-title":"Mechanisms of immune-mediated liver injury","volume":"115","author":"Adams","year":"2010","journal-title":"Toxicol. Sci"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1172\/JCI6926","article-title":"Safety and antitumor activity of recombinant soluable Apo2 ligand","volume":"104","author":"Ashkenazi","year":"1999","journal-title":"J. Clin. Invest"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B3","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/35008667","article-title":"TRAIL receptor-2 signals apoptosis through FADD and caspase-8","volume":"2","author":"Bodmer","year":"2000","journal-title":"Nat. Cell Biol"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B4","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/301527a0","article-title":"A severe combined immunodeficiency mutation in the mouse","volume":"301","author":"Bosma","year":"1983","journal-title":"Nature"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B5","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1172\/JCI74056","article-title":"ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis","volume":"124","author":"Condamine","year":"2014","journal-title":"J. Clin. Invest"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B6","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00262-012-1370-x","article-title":"TRAIL suppresses tumor growth in mice by inducing tumor-infiltrating CD4+CD25+ Treg apoptosis","volume":"62","author":"Diao","year":"2013","journal-title":"Cancer Immunol. Immunother"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B7","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1177\/0192623312447542","article-title":"Differential effect of troglitazone on the human bile acid transporters, MRP2 and BSEP, in the PXB hepatic chimeric mouse","volume":"40","author":"Foster","year":"2012","journal-title":"Toxicol. Pathol"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B8","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1158\/1078-0432.CCR-05-2635","article-title":"Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs","volume":"12","author":"Ganten","year":"2006","journal-title":"Clin. Cancer Res"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B9","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrd3003","article-title":"The safety and side effects of monoclonal antibodies","volume":"9","author":"Hansel","year":"2010","journal-title":"Nat. Rev. Drug Discov"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B10","doi-asserted-by":"crossref","first-page":"8502","DOI":"10.1158\/0008-5472.CAN-04-2599","article-title":"TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice","volume":"64","author":"Hao","year":"2004","journal-title":"Cancer Res"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B11","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1200\/JCO.2009.25.1991","article-title":"Phase I dose-escalation study of recombinant human Apo2L\/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer","volume":"28","author":"Herbst","year":"2010","journal-title":"J. Clin. Oncol"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B12","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1124\/jpet.102.040030","article-title":"Cholestasis increases tumor necrosis factor-related apoptotis-inducing ligand (TRAIL)-R2\/DR5 expression and sensitizes the liver to TRAIL-mediated cytotoxicity","volume":"303","author":"Higuchi","year":"2002","journal-title":"J. Parmacol. Exp. Ther"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B13","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/91000","article-title":"Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity","volume":"7","author":"Ichikawa","year":"2001","journal-title":"Nat. Med"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B14","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/75045","article-title":"Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand","volume":"6","author":"Jo","year":"2000","journal-title":"Nat. Med"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.toxlet.2012.08.001","article-title":"Chimeric mice with a humanized liver as an animal model of troglitazone-induced liver injury","volume":"214","author":"Kakuni","year":"2012","journal-title":"Toxicol. Lett"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B16","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1124\/dmd.104.001347","article-title":"Expression of human cytochromes P450 in chimeric mice with humanized liver","volume":"32","author":"Katoh","year":"2004","journal-title":"Drug Metab. Dispos"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B17","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1124\/dmd.105.005157","article-title":"Expression of human phase II enzymes in chimeric mice with humanized liver","volume":"33","author":"Katoh","year":"2005","journal-title":"Drug Metab. Dispos"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0022-3565(24)29298-3","article-title":"Preclinical studies to predict the disposition of Apo2L\/tumor necrosis factor-related apoptosis-inducing ligand in humans: Characterization of in vivo efficacy, pharmacokinetics, and safety","volume":"299","author":"Kelley","year":"2001","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B19","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.bbrc.2013.10.040","article-title":"A novel TK-NOG based humanized mouse model for the study of HBV and HCV infections","volume":"441","author":"Kosaka","year":"2013","journal-title":"Biochem. Biophys. Res. Commun"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B20","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86397","article-title":"Differential hepatocyte toxicity of recombinant Apo2L\/TRAIL versions","volume":"7","author":"Lawrence","year":"2001","journal-title":"Nat. Med"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B21","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/hep.24758","article-title":"Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation","volume":"55","author":"L\u00fctgehetmann","year":"2012","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B22","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1093\/toxsci\/kfp088","article-title":"Toxicity testing in the 21st century: A view from the pharmaceutical industry","volume":"110","author":"MacDonald","year":"2009","journal-title":"Toxicol. Sci"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B23","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1158\/1078-0432.CCR-04-1867","article-title":"Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2","volume":"11","author":"Motoki","year":"2005","journal-title":"Clin. Cancer Res"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B24","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.clim.2009.02.011","article-title":"TRAIL, DR4 and DR5 are upregulated in kidneys from patients with lupus nephritis and exert proliferative and proinflammatory effects","volume":"132","author":"Nguyen","year":"2009","journal-title":"Clin. Immunol"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B25","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1080\/00498250500307251","article-title":"Evaluation of mRNA expression of human drug-metabolizing enzymes and transporters in chimeric mouse with humanized liver","volume":"35","author":"Nishimura","year":"2005","journal-title":"Xenobiotica"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B26","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/364806a0","article-title":"Lethal effect of the anti-Fas antibody in mice","volume":"364","author":"Ogasawara","year":"1993","journal-title":"Nature"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B27","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/hep.25651","article-title":"Severe necroinflammatory reaction caused by natural killer cell-mediated Fas\/Fas ligand interaction and dendritic cells in human hepatocyte chimeric mouse","volume":"56","author":"Okazaki","year":"2012","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B28","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10637-017-0536-y","article-title":"Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand\/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer","volume":"36","author":"Ouyang","year":"2018","journal-title":"Invest. New Drugs"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B29","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1126\/science.276.5309.111","article-title":"The receptor for the cytotoxic ligand TRAIL","volume":"276","author":"Pan","year":"1997","journal-title":"Science"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B30","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00280-015-2712-0","article-title":"Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody\u00ae targeting the DR5 receptor","volume":"75","author":"Papadopoulos","year":"2015","journal-title":"Cancer Chemother. Pharmacol"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B31","doi-asserted-by":"crossref","first-page":"12687","DOI":"10.1074\/jbc.271.22.12687","article-title":"Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family","volume":"271","author":"Pitti","year":"1996","journal-title":"J. Biol. Chem"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B32","doi-asserted-by":"crossref","first-page":"6187","DOI":"10.1158\/1078-0432.CCR-07-0950","article-title":"Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers","volume":"13","author":"Plummer","year":"2007","journal-title":"Clin. Cancer Res"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B33","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3109\/00498254.2015.1007112","article-title":"Predictability of plasma concentration-time curves in humans using single-species allometric scaling of chimeric mice with humanized liver","volume":"45","author":"Sanoh","year":"2015","journal-title":"Xenobiotica"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B34","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/1097-0142(19920101)69:1<256::AID-CNCR2820690143>3.0.CO;2-N","article-title":"Novel tumor necrosis factor toxic effects. Pulmonary hemorrhage and severe hepatic dysfunction","volume":"69","author":"Schilling","year":"1992","journal-title":"Cancer"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B35","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3109\/00498254.2011.640716","article-title":"Evaluation of the pharmacokinetics, biotransformation and hepatic transporter effects of troglitazone in mice with humanized livers","volume":"42","author":"Schulz-Utermoehl","year":"2012","journal-title":"Xenobiotica"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B36","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.277.5327.818","article-title":"Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors","volume":"277","author":"Sheridan","year":"1997","journal-title":"Science"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B37","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2131\/jts.38.581","article-title":"Potentials and limitations of nonclinical safety assessment for predicting clinical adverse drug reactions: Correlation analysis of 142 approved drugs in Japan","volume":"38","author":"Tamaki","year":"2013","journal-title":"J. Toxicol. Sci"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B38","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/cr.2009.57","article-title":"TRAIL receptor mediates inflammatory cytokine release in an NF-kappaB-dependent manner","volume":"19","author":"Tang","year":"2009","journal-title":"Cell Res"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B39","author":"Tateno","year":"2014"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B40","doi-asserted-by":"crossref","first-page":"e0142145.","DOI":"10.1371\/journal.pone.0142145","article-title":"Generation of novel chimeric mice with humanized livers by using hemizygous cDNA-uPA\/SCID mice","volume":"10","author":"Tateno","year":"2015","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B41","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/labinvest.2012.158","article-title":"Morphological and microarray analyses of human hepatocytes from xenogeneic host livers","volume":"93","author":"Tateno","year":"2013","journal-title":"Lab. Invest"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B42","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0002-9440(10)63352-4","article-title":"Near completely humanized liver in mice shows human-type metabolic responses to drugs","volume":"165","author":"Tateno","year":"2004","journal-title":"Am. J. Pathol"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B43","doi-asserted-by":"crossref","first-page":"10087","DOI":"10.1128\/JVI.01126-15","article-title":"Human cytotoxic T lymphocyte-mediated acute liver failure and rescue by immunoglobulin in human hepatocyte transplant TK-NOG mice","volume":"89","author":"Uchida","year":"2015","journal-title":"J. Virol"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B44","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1002\/hep.21846","article-title":"Increased hepatotoxicity of tumor necrosis factor-related apoptosis-inducing ligand in diseased human liver","volume":"46","author":"Volkmann","year":"2007","journal-title":"Hepatology"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B45","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nrc.2017.28","article-title":"Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy","volume":"17","author":"Von Karstedt","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B46","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/5517","article-title":"Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo","volume":"5","author":"Walczak","year":"1999","journal-title":"Nat. Med"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B47","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1158\/1078-0432.CCR-09-2443","article-title":"TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo","volume":"16","author":"Wang","year":"2010","journal-title":"Clin. Cancer Res"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B48","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1038\/nm1660","article-title":"Critical link between TRAIL and CCL20 for the activation of TH2 cells and the expression of allergic airway disease","volume":"13","author":"Weckmann","year":"2007","journal-title":"Nat. Med"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B49","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/1074-7613(95)90057-8","article-title":"Identification and characterization of a new member of the TNF family that induces apoptosis","volume":"3","author":"Wiley","year":"1995","journal-title":"Immunity"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B50","doi-asserted-by":"crossref","first-page":"e1001628.","DOI":"10.1371\/journal.pmed.1001628","article-title":"Fialuridine induces acute liver failure in chimeric TK-NOG mice: A model for detecting hepatic drug toxicity prior to human testing","volume":"11","author":"Xu","year":"2014","journal-title":"PLoS Med"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B51","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2131\/jts.32.205","article-title":"Evaluation of human hepatocyte chimeric mice as a model for toxicological investigation using panomic approaches\u2014Effect of acetaminophen on the expression profiles of proteins and endogenous metabolites in liver, plasma and urine","volume":"32","author":"Yamamoto","year":"2007","journal-title":"J. Toxicol. Sci"},{"key":"key\n\t\t\t\t2019010308585857600_kfy228-B52","doi-asserted-by":"crossref","first-page":"e2338.","DOI":"10.1038\/cddis.2016.241","article-title":"Antitherapeutic antibody-mediated hepatotoxicity of recombinant human Apo2L\/TRAIL in the cynomolgus monkey","volume":"7","author":"Zuch de Zafra","year":"2016","journal-title":"Cell Death Dis"}],"container-title":["Toxicological Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/toxsci\/article-pdf\/167\/1\/190\/27331058\/kfy228.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T22:48:48Z","timestamp":1751842128000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/toxsci\/article\/167\/1\/190\/5093319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,9]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,9,9]]},"published-print":{"date-parts":[[2019,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/toxsci\/kfy228","relation":{},"ISSN":["1096-6080","1096-0929"],"issn-type":[{"value":"1096-6080","type":"print"},{"value":"1096-0929","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,1]]},"published":{"date-parts":[[2018,9,9]]}}}